Carmat Past Earnings Performance

Past criteria checks 0/6

Carmat's earnings have been declining at an average annual rate of -6.9%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 67.1% per year.

Key information

-6.9%

Earnings growth rate

14.9%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate67.1%
Return on equityn/a
Net Margin-770.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Carmat makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CXT Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 247-53210
31 Mar 245-54210
31 Dec 234-54220
30 Sep 232-54220
30 Jun 231-54220
31 Mar 231-54210
31 Dec 220-54210
30 Sep 221-58180
30 Jun 222-62140
31 Mar 222-62130
31 Dec 212-62120
30 Sep 211-52120
30 Jun 210-42120
31 Mar 210-40110
31 Dec 200-37100
30 Sep 200-38120
30 Jun 200-40140
31 Mar 200-41130
31 Dec 190-43130
30 Sep 190-45120
30 Jun 190-47120
31 Mar 190-44110
31 Dec 180-42110
30 Sep 180-38100
30 Jun 180-3490
31 Mar 180-3280
31 Dec 170-2970
30 Sep 170-2870
30 Jun 170-2770
31 Mar 170-2570
31 Dec 160-2360
30 Sep 160-2160
30 Jun 160-2060
31 Mar 160-1960
31 Dec 150-1860
30 Sep 150-1760
30 Jun 150-1750
31 Mar 150-1750
31 Dec 140-1850
30 Sep 140-1950
30 Jun 140-2040
31 Mar 141-1740
31 Dec 133-1540

Quality Earnings: CXT is currently unprofitable.

Growing Profit Margin: CXT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CXT is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare CXT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CXT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: CXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carmat SA is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Romain ZanaBNP Paribas Exane
Laura RobaDegroof Petercam
Maxim JacobsEdison Investment Research